NASDAQ: SGNL       Signal Genetics Cmn
Last Price Today's Change   Day's Range   Trading Volume
0.00   0.00 (0.00%)  0.00 - 0.00  0


Avg Volume (4 weeks):0
Average Price Target:-


No recent Headlines for this stock.

Business Background

miRagen Therapeutics Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of micro-ribonucleic acid (RNA)-targeted therapies. Its lead product candidates, MRG-106 and MRG-201, are in Phase I clinical trials. Its therapeutic areas of focus include cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is developing a pipeline of pre-clinical product candidates.

  Be the first to like this.


1571  6203  702  81 

Top 10 Active Counters
 SPY 258.05-5.62 
 MU 54.21-4.71 
 BAC 29.17-1.38 
 TVIX 10.57+1.05 
 XLF 26.82-0.84 
 GE 13.07-0.28 
 EEM 46.89-0.97 
 QQQ 158.51-4.29 
 UVXY 20.24+1.56 
 GDX 22.12+0.62 
Partners & Brokers